The present invention relates to Saccharomyces sp. capable of producing lactic acid with a decreased activity of pyruvate decarboxylase (PDC) and increased activities of aldehyde dehydrogenase (ALD) and acetyl-CoA synthetase (ACS), and a method of producing lactic acid from the culture medium obtained by culturing the microorganism.

Provided are a genetically engineered yeast cell having increased activity of SUL1, STR3, HXT7, ERR1, GRX8, MXR1, GRE1, MRK1, AAD10 or a combination thereof, compared to a parent cell, and also having acid tolerance, a method of preparing the same, and a method of producing lactate using the same.

Provided is recombinant Escherichia coli comprising a mutated ldhA gene. Disclosed are use of the recombinant Escherichia coli in the preparation of D-lactate, and method of preparing D-lactate by employing the recombinant Escherichia coli. In the method of preparing D-lactate, fermentation can be conducted at a high temperature (42-50 C.), and aqueous ammonia or sodium hydroxide can be used as a neutralizer during the fermentation.

Disclosed are very high optically pure D- and L-lactic acid fermentation production strains and construction methods thereof and the method for preparing very high optically pure D- and L-lactic acids using the strains, wherein the deposit number of the D-lactic acid fermentation production strain is CGMCC No. 11059, and the deposit number of the L-lactic acid fermentation production strain is CGMCC No. 11060.

One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.

A recombinant yeast cell capable of consuming glucose at an increased rate, and a method of efficiently producing glycolysis-derived products using the recombinant yeast cell.

The present invention relates to Saccharomyces sp. capable of producing lactic acid with a decreased activity of pyruvate decarboxylase (PDC) and increased activities of aldehyde dehydrogenase (ALD) and acetyl-CoA synthetase (ACS), and a method of producing lactic acid from the culture medium obtained by culturing the microorganism.

A yeast cell capable of producing lactate, a method of preparing the yeast cell, and a method of producing lactate by using the yeast cell, wherein theyeast cell has a reduced activity of rim15 protein, igo2 protein, or a combination thereof, and an increased activity of an enzyme that catalyzes conversion from pyruvate to lactate, compared to a parent cell.

The present invention provides systems and methods for detecting bacterial infection in a patient sample in vitro, comprising an enzyme having D-lactate oxidising activity, and a means for detecting a reaction product of said enzyme.

Provided is a genetically engineered yeast cell with lactate production capacity, including an enzyme that catalyzes conversion of acetaldehyde to acetyl-CoA and an enzyme that catalyzes conversion of pyruvate to lactate, which activities are increased compared to a parent cell of the yeast cell, as well as a method of producing the genetically engineered yeast cell and method of producing lactate using the genetically engineered yeast cell.